Epic Sciences

Press Releases


Epic Sciences and Its Collaborators to Present New Data at ASCO 2018

New data validates clinical utility of commercially-available Oncotype DX® AR-V7 Nucleus Detect™ test and additional tests under development for predictive medicine


Epic Sciences Presents Detection and Characterization of Rare Peripheral CTC Immunogenicity and T-Cell Activation

At the 2018 AACR annual meeting, Epic Sciences presented data from two studies demonstrating the company’s “No Cell Left Behind” detection platform’s capability to analyze potential markers of response to immuno-oncology (IO) agents, such as checkpoint inhibitors, vaccines, and CAR-T therapies.


Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer

Medicare Draft Coverage Supports Clinical Utility of the Oncotype DX AR-V7 Nucleus Detect Test, Providing 25,000 Medicare Patients with Coverage Once LCD Is Finalized


Epic Sciences to Present Single Cell PSMA Analysis to Provide Insight into Tumor Heterogeneity and Links to Response with Anti-PSMA Therapy

Epic Sciences will be presenting data, in conjunction with Endocyte Inc., on single cell PSMA analysis at ASCO GU on February 8th, 2018.


Epic Sciences to Present at the 2nd Annual CTIC Capital Cross-Border China-US Healthcare Investment Summit.

Epic Sciences is one of six select companies chosen to present


Epic Sciences launches metastatic breast cancer circulating tumor cell panel.

Epic Sciences, Inc. announces the release of its breast cancer single-cell profiling panel. The Epic breast cancer panel is the most comprehensive breast cancer biomarker panel available for characterization of circulating tumor cells (CTCs) within a blood sample.


Epic Sciences launches single-cell microsatellite and chromosomal instability genomic analysis.

New capability identifies sub-clonal tumor microsatellite instability in metastatic cancers to understand patient selection for PD-1 inhibitors, PARP inhibitors and combination therapies.